Catalent (NYSE:CTLT) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a research note released on Sunday. The brokerage issued a sell rating on the stock.

CTLT has been the subject of a number of other research reports. UBS Group reiterated a neutral rating and issued a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Royal Bank of Canada reissued a sector perform rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. Stephens reaffirmed an equal weight rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Finally, Barclays raised their price target on Catalent from $45.00 to $47.00 and gave the stock an equal weight rating in a report on Thursday, January 25th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Catalent has a consensus rating of Hold and an average target price of $52.46.

Catalent Trading Down 0.6 %

Shares of Catalent stock opened at $56.18 on Friday. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. The company has a fifty day simple moving average of $56.37 and a 200-day simple moving average of $49.31. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of -8.26, a PEG ratio of 6.09 and a beta of 1.18. Catalent has a 12-month low of $31.45 and a 12-month high of $60.20.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the company earned $0.62 EPS. The business’s revenue was down 10.2% on a year-over-year basis. On average, equities analysts forecast that Catalent will post 0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Catalent

Several institutional investors and hedge funds have recently made changes to their positions in the business. Lindbrook Capital LLC boosted its stake in shares of Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after acquiring an additional 208 shares during the last quarter. Gladius Capital Management LP acquired a new position in Catalent during the third quarter worth approximately $28,000. Exchange Traded Concepts LLC purchased a new position in shares of Catalent in the 3rd quarter worth $31,000. GAMMA Investing LLC purchased a new position in Catalent in the fourth quarter valued at approximately $33,000. Finally, Cary Street Partners Investment Advisory LLC boosted its position in Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after purchasing an additional 709 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.